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ABSTRACT 
 
The course of multiple sclerosis (MS) is extremely variable. A limited number of demographic and 
clinical variables at MS onset were described to predict time to the onset of irreversible disability. 
However, there is no general consensus concerning the power and long-term range of these predictors. 
Although pivotal trials of interferon beta and glatirameracetate in relapsing-remitting MS 
demonstrated a reduced relapse rate, it is not clear whether the onset of secondary progression is 
postponed by means of treatment. Long-term randomized control trials are of several reasons not 
possible to accomplish. The only option is observational studies.  
 
In this thesis the long-term prognosis was determined in a 50-year follow-up in the geographically 
and temporally defined “Gothenburg Incidence Cohort” (onset 1950-64, n=305). A Kaplan-Meier 
survival analysis showed that the median time to secondary progression was 14 years, to EDSS 6 (gait 
with a cane) 25 years and EDSS7 (wheelchair bound) 48 years. A score of combined onset predictors 
provided an estimate of the time to disability with a hazard ratio in the order of magnitude 2-4 (paper 
I).  
 
Further, we investigated whether first generation immunomodulating drugs in the relapsing remitting 
phase delay the time to secondary progression.  We explored the predictors as tools to adjust for 
imbalance between treated patients and historical controls. We compared the time to secondary 
progression between treated patients from the Swedish National MS Registry (disease onset 1995–
2004, n = 730) and untreated patients from the Gothenburg Incidence Cohort (n = 186) within a 12-
year survival analysis.  The treated patients exhibited a significant longer time to secondary 
progression than the historical controls (hazard ratios: men, 0.32; women, 0.53) (paper II).  
 
In order to obtain an individual prediction of the risk of secondary progression we investigated 
predictors associated with relapses throughout the course. We used Poisson regression to estimate the 
individual current risk of secondary progression at any point during the relapsing-remitting course. 
The average annual risk of secondary progression was 4.6 %. An algorithm including current age, a 
severity score of the last attack and the time elapsed since the attack predicted the yearly risk of 
secondary progression within the range 0.1-15%. This algorithm is now web-based 
(http://msprediction.com) and may be used for stratification of patients in future studies (paper III). 
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